Eastman Kodak Company: Q2 1997 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 1997, and the first half of the fiscal year. Eastman Kodak Company operates primarily in Consumer and Commercial Imaging segments. The reporting period is characterized by the integration of the Wang Laboratories software unit acquisition and the continued impact of the sale of the Office Imaging business in late 1996.
Key Financial Metrics
| Metric (in millions) | Q2 1997 | Q2 1996 | YTD 1997 | YTD 1996 |
|---|---|---|---|---|
| Total Revenues | $3,890 | $4,202 | $7,092 | $7,648 |
| Net Earnings | $368 | $440 | $517 | $714 |
| Earnings Per Share | $1.12 | $1.30 | $1.57 | $2.09 |
| Operating Cash Flow (YTD) | $93 (vs. $633 YTD 1996) | |||
| Cash & Equivalents | $371 (vs. $1,777 at Dec 31, 1996) | |||
| Short-term Borrowings | $874 (vs. $541 at Dec 31, 1996) | |||
| Long-term Borrowings | $610 (vs. $599 at Dec 31, 1996) |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 6% in Q2 and 7% year-to-date compared to 1996. This is largely attributed to the sale of the Office Imaging business in December 1996. Excluding this divestiture, sales would have increased 2% year-over-year.
- Profitability Pressure: Net earnings fell 16% in Q2 and 28% year-to-date. Earnings from operations dropped 27% year-to-date.
- Unusual Items: A significant pre-tax charge of $186 million was recorded in Q1 1997 for purchased research and development (R&D) related to the acquisition of Wang Laboratories' software unit. Excluding this charge, YTD EPS would have been $1.94.
- Segment Performance:
- Consumer Imaging: Sales up 5% (Q2) and 4% (YTD), driven by volume growth, though offset by lower prices and foreign currency headwinds.
- Commercial Imaging: Sales down 17% (Q2) and 16% (YTD), primarily due to the Office Imaging divestiture. Earnings from operations in this segment fell 44% YTD, heavily impacted by the Wang R&D charge.
- Liquidity Shift: Cash and cash equivalents dropped significantly from $1.777 billion to $371 million, driven by a $659 million stock repurchase program and the $260 million cash acquisition of Wang Laboratories.
Guidance, Outlook, and Risks
- Outlook: Management stated it is unlikely that full-year 1997 earnings per share will exceed $4.50. This guidance accounts for continuing price pressures, the stronger dollar, investments in the Advantix system, and widening losses in digital products.
- Advantix Business: The company expects losses attributable to the Advantix digital camera system in 1997 to exceed those of 1996, citing a $25 million charge for tooling write-offs in Q2.
- Digital Products: Losses on the digital products portfolio exceeded $100 million for the first six months of 1997.
- Capital Allocation: The company is utilizing cash reserves to complete a $2 billion stock repurchase program initiated in 1996.
- Risks: Key risks include the ability to implement digital product strategies, competitive actions, technological development pace, and foreign currency fluctuations.
Investor Verification Checklist
- Wang Acquisition Impact: Verify the long-term revenue contribution of the Wang Laboratories software unit against the $186 million immediate R&D charge.
- Digital Loss Trajectory: Monitor the widening losses in the digital products portfolio and the specific timeline for profitability in the Advantix system.
- Currency Sensitivity: Assess the magnitude of foreign exchange headwinds on international sales, which offset volume growth in both Consumer and Commercial segments.
- Liquidity Position: Confirm the sustainability of the $2 billion stock repurchase program given the sharp decline in cash reserves and operating cash flow.
- Office Imaging Divestiture: Evaluate whether the remaining Commercial Imaging segment can stabilize without the Office Imaging business.